In a matter involving alleged abuse of the U.S. Pharmacopeia standard setting process, CRA examined market power for product dispensed through hospital and non-hospital sites of care. CRA’s expert found that in most uses, during the relevant time period there was ample evidence of competition, finding that the manufacturer at issue was effectively price constrained by existing competition.
CRA experts win prestigious 2026 Antitrust Writing Awards
The awards recognize outstanding scholarship and advocacy in antitrust law and economics. Christian Michel, a principal in the Antitrust & Competition...